Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | RORC | P51449 | 6/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294336 | 1.00 | KCNH2 (0.50) | KCNH2RORCPTGDR2CCR1ENPP2 | |
| SCHEMBL17294222 | 0.96 | KCNH2 (0.54) | KCNH2RORCPTGDR2CCR1ENPP2 | |
| SCHEMBL17294221 | 0.96 | KCNH2 (0.54) | KCNH2RORCPTGDR2CCR1ENPP2 | |
| SCHEMBL17182295 | 0.86 | RORC (0.65) | KCNH2RORCPTGDR2 | |
| SCHEMBL30213791 | 0.86 | RORC (0.65) | KCNH2RORCPTGDR2 | |
| SCHEMBL15777172 | 0.86 | RORC (0.65) | KCNH2RORCPTGDR2 | |
| SCHEMBL17298278 | 0.85 | RORC (0.64) | KCNH2RORCPTGDR2 | |
| SCHEMBL19095653 | 0.85 | RORC (0.64) | KCNH2RORCPTGDR2 | |
| SCHEMBL17294259 | 0.85 | KCNH2 (0.49) | KCNH2RORCPTGDR2CCR1ENPP2 | |
| SCHEMBL17294260 | 0.85 | KCNH2 (0.49) | KCNH2RORCPTGDR2CCR1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106536489-B | Retinoid-related orphan receptor gamma modulators and uses thereof | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-07 | — | — | CN | disclosed |
| EP-3148975-B1 | PIPERAZINE DERIVATIVES AS ROR-GAMMA MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-11-28 | — | — | EP | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| EP-3148975-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015180612-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197978-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | KCNH2 4565/4885RORC 1/4885PTGDR2 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.